vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and DONEGAL GROUP INC (DGICA). Click either name above to swap in a different company.
DONEGAL GROUP INC is the larger business by last-quarter revenue ($236.0M vs $191.2M, roughly 1.2× Axsome Therapeutics, Inc.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -3.7%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -2.2%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Donegal Group Inc. is a regional US insurance holding company offering personal and commercial property and casualty insurance products. It serves Mid-Atlantic, Midwest, and Southern US customers, delivering tailored coverage for individuals, families, and small to medium businesses.
AXSM vs DGICA — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $236.0M |
| Net Profit | — | $11.5M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | — |
| Net Margin | — | 4.9% |
| Revenue YoY | 57.4% | -3.7% |
| Net Profit YoY | — | -54.3% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | $236.0M | ||
| Q4 25 | $196.0M | $239.8M | ||
| Q3 25 | $171.0M | $245.9M | ||
| Q2 25 | $150.0M | $247.1M | ||
| Q1 25 | $121.5M | $245.2M | ||
| Q4 24 | $118.8M | $250.0M | ||
| Q3 24 | $104.8M | $251.7M | ||
| Q2 24 | $87.2M | $246.8M |
| Q1 26 | — | $11.5M | ||
| Q4 25 | $-28.6M | $17.2M | ||
| Q3 25 | $-47.2M | $20.1M | ||
| Q2 25 | $-48.0M | $16.9M | ||
| Q1 25 | $-59.4M | $25.2M | ||
| Q4 24 | $-74.9M | $24.0M | ||
| Q3 24 | $-64.6M | $16.8M | ||
| Q2 24 | $-79.3M | $4.2M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 8.7% | ||
| Q3 25 | -27.0% | 10.2% | ||
| Q2 25 | -24.5% | 8.3% | ||
| Q1 25 | -46.9% | 12.7% | ||
| Q4 24 | -61.1% | 11.9% | ||
| Q3 24 | -59.8% | 8.1% | ||
| Q2 24 | -89.5% | 2.0% |
| Q1 26 | — | 4.9% | ||
| Q4 25 | -14.6% | 7.2% | ||
| Q3 25 | -27.6% | 8.2% | ||
| Q2 25 | -32.0% | 6.8% | ||
| Q1 25 | -48.9% | 10.3% | ||
| Q4 24 | -63.1% | 9.6% | ||
| Q3 24 | -61.7% | 6.7% | ||
| Q2 24 | -91.0% | 1.7% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | — | ||
| Q2 25 | $-0.97 | — | ||
| Q1 25 | $-1.22 | — | ||
| Q4 24 | $-1.54 | — | ||
| Q3 24 | $-1.34 | — | ||
| Q2 24 | $-1.67 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $649.1M |
| Total Assets | $713.6M | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $649.1M | ||
| Q4 25 | $88.3M | $640.4M | ||
| Q3 25 | $73.7M | $627.4M | ||
| Q2 25 | $73.1M | $605.7M | ||
| Q1 25 | $53.2M | $584.7M | ||
| Q4 24 | $57.0M | $545.8M | ||
| Q3 24 | $92.9M | $513.4M | ||
| Q2 24 | $102.9M | $484.1M |
| Q1 26 | $713.6M | $2.4B | ||
| Q4 25 | $689.8M | $2.4B | ||
| Q3 25 | $669.3M | $2.4B | ||
| Q2 25 | $639.8M | $2.4B | ||
| Q1 25 | $596.7M | $2.4B | ||
| Q4 24 | $568.5M | $2.3B | ||
| Q3 24 | $561.5M | $2.3B | ||
| Q2 24 | $548.2M | $2.3B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
DGICA
Segment breakdown not available.
